Literature DB >> 19528281

Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis.

Takahiro Takazono1, Koichi Izumikawa, Tomo Mihara, Kosuke Kosai, Tomomi Saijo, Yoshifumi Imamura, Taiga Miyazaki, Masafumi Seki, Hiroshi Kakeya, Yoshihiro Yamamoto, Katsunori Yanagihara, Shigeru Kohno.   

Abstract

Targeted intrapulmonary delivery of drugs may reduce systemic toxicity and improve treatment efficacy. In the current study, we evaluated the effects of a combination treatment consisting of inhalation of aerosolized liposomal amphotericin B (L-AMB) with intraperitoneal administration of micafungin (MCFG) against murine invasive pulmonary aspergillosis. The combination of aerosolized L-AMB with intraperitoneal MCFG significantly improved the survival rate, and the fungal burdens and histopathology findings after this treatment were superior to those of the control and both monotherapy groups.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528281      PMCID: PMC2715619          DOI: 10.1128/AAC.00285-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  B D Alexander; E S Dodds Ashley; R M Addison; J A Alspaugh; N J Chao; J R Perfect
Journal:  Transpl Infect Dis       Date:  2006-03       Impact factor: 2.228

3.  Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity.

Authors:  Elisabeth J Ruijgrok; Marcel H A Fens; Irma A J M Bakker-Woudenberg; Els W M van Etten; Arnold G Vulto
Journal:  J Pharm Pharmacol       Date:  2005-10       Impact factor: 3.765

4.  Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice.

Authors:  T Otsubo; K Maruyama; S Maesaki; Y Miyazaki; E Tanaka; T Takizawa; K Moribe; K Tomono; T Tashiro; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

5.  Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.

Authors:  Koji Takemoto; Yutaka Yamamoto; Yutaka Ueda; Yoshihiro Sumita; Koichiro Yoshida; Yoshihito Niki
Journal:  J Antimicrob Chemother       Date:  2006-01-30       Impact factor: 5.790

Review 6.  Aspergillosis case-fatality rate: systematic review of the literature.

Authors:  S J Lin; J Schranz; S M Teutsch
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

7.  Efficacy of intravenous itraconazole against invasive pulmonary aspergillosis in neutropenic mice.

Authors:  Shigeru Tansho; Shigeru Abe; Hiroko Ishibashi; Shinichi Torii; Hisaya Otani; Yasuo Ono; Hideyo Yamaguchi
Journal:  J Infect Chemother       Date:  2007-01-18       Impact factor: 2.211

8.  Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.

Authors:  John R Graybill; Rosie Bocanegra; Gloria M Gonzalez; Laura K Najvar
Journal:  J Antimicrob Chemother       Date:  2003-09-12       Impact factor: 5.790

9.  Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.

Authors:  Bart J Rijnders; Jan J Cornelissen; Lennert Slobbe; Martin J Becker; Jeanette K Doorduijn; Wim C J Hop; Elisabeth J Ruijgrok; Bob Löwenberg; Arnold Vulto; Pieternella J Lugtenburg; Siem de Marie
Journal:  Clin Infect Dis       Date:  2008-05-01       Impact factor: 9.079

  9 in total
  5 in total

Review 1.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

2.  Synergistic Antifungal Effect of Amphotericin B-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles and Ultrasound against Candida albicans Biofilms.

Authors:  Min Yang; Kaiyue Du; Yuru Hou; Shuang Xie; Yu Dong; Dairong Li; Yonghong Du
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

3.  Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebremariam; Guanpingsheng Luo; Yue Fu; Samuel W French; John E Edwards; Brad Spellberg
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

Review 4.  Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Front Microbiol       Date:  2017-05-16       Impact factor: 5.640

Review 5.  Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections.

Authors:  Kévin Brunet; Jean-Philippe Martellosio; Frédéric Tewes; Sandrine Marchand; Blandine Rammaert
Journal:  Pharmaceutics       Date:  2022-03-14       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.